BeiGene, Ltd, exhibits an upward trend in business proceedings and impressive operational milestones. Most notably, it has witnessed a growth of 8.9%, scheduled an EGM for significant corporate changes, and announced the appointment of
Giancarlo Benelli as
Head of Europe. Noteworthy advancements include BeiGene's
B7H4 ADC Milestone Achievement with Duality Biologics, entering a global licensing agreement for a
MAT2A Inhibitor, and an improved operating income expected by 2025. Despite facing litigation, BeiGene has settled its case against a generic filer of
BRUKINSA. BeiGene's recent rebranding as ‘
BeOne Medicines’ affirms its mission against cancer with key plans to begin numerous clinical trials. With this rebranding, its NASDAQ ticker symbol will change to 'ONC'. Furthermore, BeiGene has a robust hematology portfolio with innovative B-cell malignancies set to be highlighted at ASH 2024 and received approval from the European Commission for BeiGene’s TEVIMBRA for advanced cancer treatments. Entering its next phase of global growth, BeiGene has opened a flagship U.S biologics manufacturing facility and continues to expand to more patients worldwide.
BeiGene, Ltd. News Analytics from Mon, 26 Feb 2024 08:00:00 GMT to Fri, 17 Jan 2025 09:13:39 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor 5
